The Eurasian Journal of Medicine
Review

Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19

1.

Department of Pharmacy, Riverside Health System, Newport News, VA, USA

2.

Department of Internal Medicine, Riverside Health System, Newport News, VA, USA

3.

Department of Family Medicine, Riverside Health System, Newport News, VA, USA

4.

Department of Pulmonary and Critical Care Medicine, Riverside Health System, Newport News, VA, USA

Eurasian J Med 2021; 53: 137-143
DOI: 10.5152/eurasianjmed.2021.20384
Read: 440 Downloads: 143 Published: 28 May 2021

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been substantial progress in the pharmacologic treatment and supportive care of patients hospitalized with active COVID-19 infections. To date there have been numerous medications trialed for COVID-19 management. In this review, our objective is to provide a comprehensive review of the primary literature and clinical applications surrounding some of the prominent drugs and medication classes that have been utilized in those suffering from COVID-19 infections. The medications reviewed in this article include: hydroxychloroquine, remdesivir, azithromycin, dexamethasone, melatonin, tocilizumab, ascorbic acid, and zinc. The medication classes reviewed include: anticoagulation, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, convalescent plasma, non-steroidal anti-inflammatory drugs, human recombinant soluble ACE2, and the BNT162b2 mRNA COVID-19 vaccine.

Cite this article as: Hall K, Mfone F, Shallcross M, Pathak V. Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19. Eurasian J Med 2021; 53(2): 137-43.

Files
EISSN 1308-8742